ab-1009
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2025 (NCT07282847)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- Lysosomal alpha-glucosidaseSupplementation
GAA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07282847 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Asklepios BIoPharmaceutical, Bayer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Asklepios BIoPharmaceutical | For profit | 1 | 1 | 1 | 2025 |
| Bayer | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1